Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Short Interest Down 58.3% in July

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 1,630 shares, a drop of 58.3% from the July 15th total of 3,905 shares. Based on an average daily volume of 20 shares, the days-to-cover ratio is presently 81.5 days.

Towa Pharmaceutical Price Performance

TWAPF remained flat at $25.98 during trading on Monday. The stock’s fifty day simple moving average is $25.72 and its two-hundred day simple moving average is $25.47. Towa Pharmaceutical has a fifty-two week low of $25.71 and a fifty-two week high of $26.00.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded shares of Towa Pharmaceutical to an “overweight” rating in a report on Friday, June 12th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Towa Pharmaceutical has a consensus rating of “Buy”.

Towa Pharmaceutical Company Profile

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.